BIOFRONTERA INC.

(BFRI)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
1.410 USD   +2.92%
09:15aBIOFRONTERA : Reports Second Quarter 2022 Financial Results and Provides a Business Update - Form 8-K
PU
08:42aBIOFRONTERA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08:39aEarnings Flash (BFRI) BIOFRONTERA Posts Q2 Revenue $4.5M, vs. Street Est of $4.54M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biofrontera Inc.(NasdaqCM:BFRI) dropped from Russell Microcap Value Index

06/24/2022 | 12:00am EDT

Biofrontera Inc.(NasdaqCM:BFRI) dropped from Russell Microcap Value Index


© S&P Capital IQ 2022
All news about BIOFRONTERA INC.
09:15aBIOFRONTERA : Reports Second Quarter 2022 Financial Results and Provides a Business Update..
PU
08:42aBIOFRONTERA INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
08:39aEarnings Flash (BFRI) BIOFRONTERA Posts Q2 Revenue $4.5M, vs. Street Est of $4.54M
MT
08:34aBiofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business ..
GL
08/04Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
GL
08/04Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
AQ
08/01Biofrontera's Management, Supervisory Boards Recommend Shareholders Reject Deutsche Bal..
MT
08/01Biofrontera Receives Australian Patent for Photodynamic Therapy to Treat Skin Diseases
MT
08/01Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted..
GL
07/28BIOFRONTERA : Announces Exercise of Existing Warrants and Issuance of Warrants in Private ..
PU
More news
Analyst Recommendations on BIOFRONTERA INC.
More recommendations
Financials (USD)
Sales 2022 32,8 M - -
Net income 2022 -7,56 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,66x
Yield 2022 -
Capitalization 26,7 M 26,7 M -
Capi. / Sales 2022 0,81x
Capi. / Sales 2023 0,49x
Nbr of Employees 69
Free-Float 57,8%
Chart BIOFRONTERA INC.
Duration : Period :
Biofrontera Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,41 $
Average target price 15,50 $
Spread / Average Target 999%
EPS Revisions
Managers and Directors
Erica L. Monaco Chief Executive, Operating & Financial Officer
Erica Gates Controller, CAO & Senior Director-Finance
Hermann Lübbert Executive Chairman
Armin Ollig Vice President-Information Technology
Daniel Hakansson General Counsel & Head-Compliance
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA INC.-81.25%26
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211